A recent study published in the New England Journal of Medicine has found that tirzepatide (Zepbound) outperformed semaglutide (Wegovy) in treating obesity. Over a 72-week period, participants on tirzepatide lost an average of 20.2% of their body weight, compared to 13.7% for those on semaglutide. Additionally, tirzepatide users experienced greater reductions in waist circumference and systolic blood pressure.
The SURMOUNT-5 trial, which was conducted by Weill Cornell Medicine and Eli Lilly, involved 751 participants with obesity or overweight. The study found that tirzepatide led to significant weight loss, with an average reduction of 50.3 pounds for those on the treatment. Participants on tirzepatide were also more likely to achieve reductions in body weight of 10-25%.
The researchers noted that the trial’s results provide further evidence for the effectiveness of tirzepatide in treating obesity. The study was sponsored by Eli Lilly, and its findings may shed light on the cardiovascular risk reduction capabilities of tirzepatide.
While safety concerns were raised during the trial, most adverse events were gastrointestinal-related and mild-to-moderate in severity. Fewer participants discontinued treatment due to any adverse events compared to semaglutide. The study’s results have significant implications for the treatment of obesity and highlight the potential benefits of tirzepatide.
Source: https://www.medpagetoday.com/endocrinology/obesity/115549